iifl-logo

Most Read News

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Karvy Customer: For activating your account click here.
Download App
image

Recovery in volumes post destocking for beverage cans, fall in energy costs and strength in auto sheets have driven steady uptick in Ebitda/t and Q4 is expected at long time guidance of US$525/t.

image

AstraZeneca's revenue for the nine months ending December 31, 2023, increased by over 28% year on year to ₹939 Crore. Innovative compounds such as Tagrisso (osimertinib) for lung cancer, Lynparza (olaparib) for ovarian cancer, Imfinzi (durvalumab), Fasenra (benralizumab) for asthma, and Calquence (acalabrutinib) for lymphoma drove growth.

image

Sheetal Agarwal of IIFL in conversation with management of the IPO bound company. Edited Excerpts:

image

The 20.76% yoy growth in mutual fund folios in February 2024, is the best show in the last one year.

image

GMs in Q2-Q3FY24 were favourably impacted by mix and input prices while CPCB4+ was not margin dilutive, reinforcing its targeted GM range of 34-35%. KKC guides operating leverage to be a larger driver of OPM over the medium-term given rated capacity utilisation of 65% levels (90% of manned capacity).

image

According to the company's exchange statement, the order is projected to be implemented in about three years, with a total cost of ₹543 Crore.

image

Ashish Sehgal, the company's chief growth officer for ad revenue, will report directly to Goenka following Rahul Johri's resignation as revenue and monetisation vertical head. In keeping with the new lateral structure, Sehgal will now collaborate closely with Goenka to optimise value for advertising. All other Johri reportees will report to Goenka's office.

image

According to figures released last Friday, non-farm payrolls climbed by 275,000 jobs last month, exceeding economists' projections of 200,000 job increases.

image

The stocks affected by the F&O ban are Manappuram Finance, Mahanagar Gas, SAIL, Tata Chemicals, and ZEEL.

image

Sun Pharmaceutical Industries Inc is recalling 47,520 bottles (40mg) and 7,488 bottles (80 mg) of the drug owing to deviations from Current Good Manufacturing Practice requirements (CGMP), the company noted. The USFDA reported microbial contamination in standing water within the duct of the manufacturing equipment," the regulatory body highlighted.

Image
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2026, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

ISO certification icon
We are ISO/IEC 27001:2022 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.